6th April 2021 Product update: rapidvirology staff writer
Collection Tube that Inactivates and Stabilizes SARS-CoV-2 is Cleared by FDA
Zymo Research has announced that the U.S. Food and Drug Administration (FDA) has cleared its DNA/RNA Shield™ Collection Tube as a Class II medical device. The FDA’s 510(k) clearance allows the product to be used as an in-vitro diagnostic (IVD) device for COVID-19 testing.
Specifically granted for COVID-19 testing, the DNA/RNA Shield™ Collection device is the first FDA-cleared technology that inactivates the virus and preserves the SARS-CoV-2 RNA.
This provides for the safety of frontline healthcare and laboratory workers. The SARS-CoV-2 virus is effectively inactivated, which allows the sample to be safely handled, transported, and stored. The viral RNA is stabilized at ambient temperature for prolonged periods for robust analysis via downstream RT-PCR.
“DNA/RNA Shield had a proven track record in various infectious disease applications prior to the current pandemic, facilitating its rapid adoption and deployment in the early stages of the COVID outbreak,” said Dr. Marc Van Eden, Vice President of Business Development at Zymo Research.
The product consists of a tube filled with Zymo Research’s proprietary DNA/RNA Shield™ transport medium. The transport medium ensures the stability of the SARS-CoV-2 RNA during sample transportation and storage for up to 28 days at ambient temperatures. The DNA/RNA Shield transport media may be kitted with a swab, sputum collection kit, or as a tube alone.
The technology is compatible with upper and lower respiratory human specimens suspected of containing SARS-CoV-2. Specimens collected and stored in a DNA/RNA Shield™ Collection Tube are suitable for use with appropriate molecular diagnostic tests.
For more details, visit Zymo Research’s website or contact them via the 'Request Information' button provided below.
Date Published: 6th April 2021
Source article link: View
Note: This content has been edited by a rapidvirology.com staff writer for style and content.